Cólera y otras infecciones del género Vibrio

  1. Carmona-Torre, F.
  2. Yuste, J.R.
  3. del Pozo, J.L.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2018

Título do exemplar: Enfermedades infecciosas (II): Infecciones por bacilos Gram negativos

Serie: 12

Número: 50

Páxinas: 2952-2962

Tipo: Artigo

DOI: 10.1016/J.MED.2018.02.012 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

Introduction In recent years, an increase in the average annual incidence of Vibrio infections has been reported, probably related to global climate change. This includes cholera, a secretory diarrhoea caused by toxigenic strains of Vibrio cholerae serogroups O1 and O139. Pathogenic Infections caused by the genus Vibrio produce diverse clinical manifestations, from gastrointestinal syndromes (of greater or lesser severity) to cutaneous infections and lethal septicaemia. Diagnosis The epidemiological context as well as the use of appropriate culture media are keys, in conjunction with biochemical and agglutination tests. Treatment It will vary depending on the clinical presentation, ranging from oral or intravenous fluid replacement, with administration of antibiotics in the most severe cases, until debridement of the necrotic tissues in cases of severe cutaneous involvement.

Referencias bibliográficas

  • Bryce J, Boschi-Pinto C, Shibuya K, Black RE. WHO estimates of the causes of death in children. The Lancet. 2005;365(9465):1147-52.
  • Cholera vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85(13):117-28.
  • Clemens JD, Nair GB, Ahmed T, Qadri F, Holmgren J. Cholera. The Lancet. 2017.
  • Ali M, Nelson AR, López AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9(6):e0003832.
  • Deen JL, von Seidlein L, Sur D, Agtini M, Lucas ME, López AL. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis. 2008;2(2):e173.
  • Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. Cholera. The Lancet. 2012;379(9835):2466-76.
  • Lipp EK, Huq A, Colwell RR. Effects of global climate on infectious disease: the cholera model. Clin Microbiol Rev. 2002;15(4):757-70.
  • Rebaudet S, Sudre B, Faucher B, Piarroux R. Cholera in coastal Africa: a systematic review of its heterogeneous environmental determinants. J Infect Dis. 2013;208Suppl1:S98-106.
  • Chowdhury FR, Nur Z, Hassan N, von Seidlein L, Dunachie S. Pandemics, pathogenicity and changing molecular epidemiology of cholera in the era of global warming. Ann Clin Microbiol Antimicrob. 2017;16(1):10.
  • Waldor MK, Mekalanos JJ. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science. 1996;272(5270):1910-4.
  • Nelson EJ, Harris JB, Morris JG, Jr., Calderwood SB, Camilli A. Cholera transmission: the host, pathogen and bacteriophage dyna-mic. Nat Rev Microbiol. 2009;7(10):693-702.
  • Safa A, Nair GB, Kong RY. Evolution of new variants of Vibrio cholerae O1. Trends Microbiol. 2010;18(1):46-54.
  • Talkington D, Bopp C, Tarr C, Parsons MB, Dahourou G, Freeman M. Characterization of toxigenic Vibrio cholerae from Haiti, 2010-2011. Emerg Infect Dis. 2011;17(11):2122-9.
  • Silva AJ, Benítez JA. Vibrio cholerae biofilms and cholera pathogenesis. PLoS Negl Trop Dis. 2016;10(2):e0004330.
  • Davies HG, Bowman C, Luby SP. Cholera : management and prevention. J Infec. 2017;74:S66-S73.
  • Benett JE, Dolin R, Blaser M, editors. Mandell, Douglas, and Bennett’s Principles and practice of infectious diseases. 8ª ed. Philadelphia: Elsevier Saunders; 2015.
  • Interim Guidance Document on Cholera Surveillance. 2017.
  • Walton DA, Ivers LC. Responding to cholera in post earthquake Haiti. N Engl J Med. 2011;364(1):3-5.
  • Ramakrishna BS, Venkataraman S, Srinivasan P, Dash P, Young GP, Binder HJ. Amylase-resistant starch plus oral rehydration solution for chole-ra. N Engl J Med. 2000;342(5):308-13.
  • Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML. Single dose azithromycin for the treatment of cholera in adults. N Engl J Med. 2006;354(23):2452-62.
  • Kaushik JS, Gupta P, Faridi MM, Das S. Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial. Indian Pediatr. 2010;47(4):309-15.
  • Khan WA, Bennish ML, Seas C, Khan EH, Ronan A, Dhar U. Randomised controlled comparison of single dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet. 1996;348(9023):296-300.
  • Qadri F, Wierzba TF, Ali M, Chowdhury F, Khan AI, Saha A. Efficacy of a Single Dose, Inactivated Oral Cholera Vaccine in Bangladesh. N Engl J Med. 2016;374(18):1723-32.
  • Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster randomised, double-blind, placebo controlled trial. Lancet Infec Dis. 2013;13(12):1050-6.
  • Baker-Austin C, Trinanes J, González-Escalona N, Martínez-Urtaza J. Non-cholera vibrios: The microbial barometer of climate change. Trends Microbiol. 2017;25(1):76-84.
Fonte de datos: Dialnet